Skip to main content
. 2014 Aug 29;9(8):e106422. doi: 10.1371/journal.pone.0106422

Figure 1. Albumin binding peptide (ABP) extends the serum persistence of VNA bioactivity.

Figure 1

(A) Protection from BoNT/A1 in mice treated with Trx/H7/B5 or Trx/H7/B5/ABP at various times prior to intoxication. Groups of five mice each (60 mice total) were treated with a known protective dose of 2 µg (40 pm) VNA and later challenged with 10 LD50 of BoNT/A1 at the indicated times post-treatment. Bars indicate the % survival: Trx/H7/B5, white bar; Trx/H7/B5/ABP, black bar. Groups with no survival show a short bar ending at 0. A delta (Δ) indicates that all mice in this group displayed discernable abdominal breathing symptoms of botulism. An asterisk indicates a significant difference (p<0.05) from the control group. Results reported are representative of three similar studies. (B) Minimum dose of Trx/H7/B5/ABP that protects from 10 LD50 BoNT/A1. Groups of five mice (25 mice total) were treated with the indicated dose of Trx/H7/B5/ABP and then challenged 6 hours later with 10 LD50 BoNT/A1. Black bars indicate % survival and a delta (Δ) indicates that surviving mice displayed severe abdominal breathing symptoms of botulism. An asterisk indicates a significant difference (p<0.05) from the control group. Results reported are representative of three similar studies.